| Literature DB >> 34959581 |
Marzia Puccioni-Sohler1,2,3, Samya J da Silva1, Luiz C S Faria2, David C B I Cabral4, Mauro J Cabral-Castro2,5.
Abstract
Dengue (DENV) and chikungunya viruses (CHIKV) cause severe neurological complications, sometimes undiagnosed. Therefore, the use of more accessible neuroinflammatory biomarkers can be advantageous considering their diagnostic and prognostic potential for aggravated clinical outcomes. In this study, we aimed to evaluate neopterin and C-X-C motif chemokine ligand 10 (CXCL-10) in cerebrospinal fluid (CSF) for the diagnosis of neuroinvasive DENV and CHIKV. We analyzed the CSF of 66 patients with neurological disorders, comprising 12 neuroinvasive DENV/CHIKV, 20 inflammatory control (viral, bacterial, and fungal meningitis, and autoimmune disorders), and 24 noninflammatory control (cerebrovascular disease, dementia, neoplasm). There was no difference between the concentration of CSF neopterin in the neuroinvasive DENV/CHIKV and control groups. However, there was a significant difference in the CXCL-10 level when comparing the neuroinvasive DENV/CHIKV group and the non-inflammatory control (p < 0.05). Furthermore, we found a linear correlation between neopterin and CXCL-10 CSF levels in the three groups. For the DENV/CHIKV neuroinvasive diagnosis, the ROC curve showed the best cut-off values for CSF neopterin at 11.23 nmol/L (sensitivity of 67% and specificity of 63%), and for CSF CXCL-10 at 156.5 pg/mL (91.7% sensitivity and specificity). These results show that CXCL-10 in CSF represents an accurate neuroinflammatory biomarker that may contribute to neuroinvasive DENV/CHIKV diagnosis.Entities:
Keywords: CXCL-10; cerebrospinal fluid; chikungunya virus; dengue virus; inflammatory biomarker; neopterin
Year: 2021 PMID: 34959581 PMCID: PMC8706264 DOI: 10.3390/pathogens10121626
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
General characteristics of the patients and analysis of the inflammatory marker concentrations in the DENV and CHIKV neuroinvasive group (group A), inflammatory control group (group B), and non-inflammatory control group (group C).
| Group A, DENV and CHIKV Neuroinvasive ( | Group B, Inflammatory Control ( | Group C, Non- Inflammatory Control ( | ||||
|---|---|---|---|---|---|---|
| A × B | A × C | B × C | ||||
|
| ||||||
| Female, n (%) | 8 (66.7%) | 10 (50%) | 18 (75%) | 0.263 | <0.999 | >0.999 |
| 61 (33–64) | 37 (30–53.3) | 48.5 (31.8–72.5) | 0.3485 | 0.5464 | >0.999 | |
| 7.5 (1–60.5) | 34 (19–149.5) | 1 (1–2) | 0.0419 ** | 0.0441 ** | <0.0001 ** | |
| 63 (43–79) | 86.5 (67–231.3) | 27 (21.25–35.75) | 0.1849 | 0.0045 ** | <0.0001 ** | |
| 63 (32.8–80) | 60 (41.5–80.8) | 70.5 (62–87) | >0.999 | 0.4887 | 0.1579 | |
| 16.4 (6.85–58.5) | 61.2 (19.5–97.6) | 9.6 (5.4–18.7) | 0.1912 | 0.3096 | 0.0001 ** | |
| 1056 (215.8–1876) | 3266 (702.5–7462) | 70.4 (29.7–98) | 0.3396 | 0.0011 ** | <0.0001 ** | |
The sex data are expressed in frequency (%); age (years); the cytology, protein, glucose, neopterin, and CXCL-10 measures are expressed in median and interquartile range (IQR) Q1–Q3. Statistical significance of the inflammatory markers was assessed between the groups (A × B, A × C, B × C) using the Kruskal–Wallis test and Dunn’s test of multiple comparisons. Reference values: cell count ≤ 4 cells/mm3, protein 15–40 mg/dL, glucose 45–70 mg/dL. ** p < 0.05—statistical significance.
Figure 1CSF analysis from the different groups of patients (neuroinvasive arboviruses, inflammatory control, non-inflammatory control). The Kruskal–Wallis non-parametric ANOVA was applied to assess whether there were statistically significant differences in the cell count in CSF (A), concentration of protein in CSF (B), neopterin in CSF (C), and CXCL-10 in CSF (D) between the groups. For further analysis, Dunn’s multiple comparison tests were used to analyze the specific group pairs. p < 0.05: statistical significance.
Figure 2Correlation between CXCL-10 and neopterin in each group and between CXCL-10 and cell count in inflammatory control group: (A) neuroinvasive arboviruses group; (B) inflammatory group; (C) non-inflammatory control group; (D) correlation between CXCL-10 and cell count in the inflammatory group. Each dot represents 1 sample. Correlation coefficient (r) was calculated using the Spearman test; r and p values are shown. For the correlation between CXCL-10 and neopterin, the Spearman test demonstrated a very strong correlation (r = 0.7273; p = 0.0096) in neuroinvasive arboviruses group, and a strong correlation in inflammatory control group (r = 0.6812; p = 0.0009) and non-inflammatory control group (r = 0.5313; p = 0.0075). The correlation between CXCL-10 and cell count in neuroinvasive arboviruses group was strong (r = 0.6822; p = 0.0009). Reference values of Spearman test: r ≥ 0.70 is very strong correlation, r = 0.40 to 0.69 is a strong correlation, r = 0.30 to 0.39 is a moderate correlation, r = 0.20 to 0.29 is a weak correlation, and r = 0.01 to 0.19 is a negligible correlation or non-correlation. p < 0.05 values are significant.
Figure 3ROC curve comparing neopterin and CXCL-10 in CSF samples. The ROC curve was used to express the non-parametric values found by Dunn’s test, and p <0.05 values are significant. The cut-off values that showed the best performance of sensitivity and specificity of the inflammatory markers neopterin and CXCL-10 in CSF samples were selected for the groups of DENV and neuroinvasive CHIKV, inflammatory control, and non-inflammatory control. (A) Neopterin in CSF from neuroinvasive arbovirus group versus non-inflammatory control; (B) Neopterin in CSF from inflammatory control versus non-inflammatory control; (C) CXCL-10 in CSF from neuroinvasive arbovirus group versus non-inflammatory control; (D) CXCL-10 in CSF from inflammatory control versus non-inflammatory control.